ArticlePediatric pulmonology2026
Knowledge and Attitudes of Ontario Pediatricians Related to Existing and New Respiratory Syncytial Virus (RSV) Prevention Products: A Cross-Sectional Study.
Article in Pediatric pulmonology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
introductionNew RSV prevention products show strong potential, but their success depends on wide acceptance and use. We assessed Ontario pediatricians' knowledge and attitudes about these products before their introduction to highlight opportunities and barriers.
methodsIn March-April 2024, Pediatricians Alliance of Ontario newsletter subscribers (n = 1566) were invited to complete an online survey on RSV knowledge and attitudes. Descriptive analyses with a complete-case approach assessed responses.
resultsOf 117 responses (7% response rate), we retained 104 confirmed as from pediatricians with complete demographic data, including 81% (84/104) general pediatricians and 19% (20/104) subspecialists. Most worked in primary care (40%; 42/104), community hospitals (32%; 33/104), and urban centers (63%; 65/104), and had ≥ 10 years' experience (81%; 83/104). They had high awareness of provincial recommendations (91%; 94/103) and knowledge of severe RSV disease risk factors (Figure 2). While 83% (82/99) always recommended palivizumab to eligible patients, only 34% (34/99) reported that all eligible patients always received it. Over 90% were likely to recommend nirsevimab (91%; 89/98), but 66% (65/98) expected to administer it. Top anticipated barriers included the introduction of a new product (69%; 25/36) and concern for adverse effects (69%; 41/59). The likelihood of recommending a maternal vaccine over nirsevimab was 45% (44/98), while 44% (43/98) were neutral.
conclusionOntario pediatricians were knowledgeable and supportive of RSV prevention products. However, they have experienced barriers with palivizumab, and they anticipated barriers with nirsevimab and the maternal RSV vaccine. As other jurisdictions look to implement new RSV prevention products, acknowledging and addressing anticipated barriers may promote acceptance and use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.